Cardiff Oncology, Inc., a clinical-stage biotechnology firm located in San Diego, California, is dedicated to developing innovative medical treatments for cancer patients. Its lead therapeutic agent is onvansertib, an oral and selective inhibitor of Polo-like Kinase 1 (PLK1), which is being investigated for various anti-cancer applications, including clinical trials for metastatic colorectal cancer. The company's pipeline further includes CY140, an inhibitor targeting PLK1, PLK2, and PLK3, currently progressing through Phase 1/2 studies for both solid tumors and leukemias.